Comment
doi: 10.1136/annrheumdis-2018-214757.
Epub 2018 Nov 28.
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
Affiliations
- PMID: 30487149
- DOI: 10.1136/annrheumdis-2018-214757
Item in Clipboard
Comment
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
Ann Rheum Dis.
2020 Feb.
No abstract available
Keywords: DMARDs (biologic); anti-TNF; psoriatic arthritis; rheumatoid arthritis; spondyloarthritis.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20. Ann Rheum Dis. 2020. PMID: 30573653 No abstract available.
Comment on
-
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
